This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Adstiladrin for high-grade, BCG unresponsive non-muscle-invasive bladder cancer

< Back

Adstiladrin for high-grade, BCG unresponsive non-muscle-invasive bladder cancer


Cancer and Palliative Care

February 2019

Adstiladrin is currently in clinical development for the treatment of patients with high-grade non-muscle-invasive bladder cancer (NMIBC). It is being developed particularly for NMIBC that is not responsive to Bacillus Calmette-Guerin (BCG) therapy, the current main treatment option for early bladder cancer. Bladder cancer starts in the inner lining of the bladder and the most common symptom is passing blood in urine. NMIBC is an early bladder cancer and is the most common type. High-grade NMIBC means the cancer is more likely to grow and spread quickly and also more likely to come back after initial treatment.
Adstiladrin is given by catheter directly into the bladder. It consists of a type of virus that is able to introduce a gene into cells of the bladder. This gene then stimulates the cells of the bladder to produce high quantities of a protein that the body uses to fight cancer. This in turn enhances the body’s natural defences against the cancer. If licensed, Adstiladrin will offer an advanced (gene) therapy treatment option for patients with high-grade NMIBC that are BCG unresponsive.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts